Insider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $44,167.77 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 1,367 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $32.31, for a total transaction of $44,167.77. Following the completion of the transaction, the executive vice president now directly owns 48,017 shares in the company, valued at $1,551,429.27. This represents a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Eric Swayze also recently made the following trade(s):

• On Thursday, January 16th, Eric Swayze sold 7,154 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $32.84, for a total transaction of $234,937.36.
• On Tuesday, November 12th, Eric Swayze sold 1,194 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $37.92, for a total transaction of $45,276.48.

Ionis Pharmaceuticals Trading Up 4.8 %

Shares of NASDAQ:IONS opened at $33.17 on Thursday. The business’s 50-day moving average is $34.94 and its 200 day moving average is $39.84. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82. Ionis Pharmaceuticals, Inc. has a 1 year low of $31.03 and a 1 year high of $52.34. The firm has a market capitalization of $5.24 billion, a P/E ratio of -13.59 and a beta of 0.34.

Analyst Ratings Changes

Several research analysts have commented on IONS shares. Needham & Company LLC restated a “buy” rating and set a $60.00 price objective on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. William Blair restated an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Piper Sandler lowered their price objective on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Guggenheim cut their target price on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, October 9th. Finally, StockNews.com lowered shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Ionis Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $60.65.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC boosted its stake in Ionis Pharmaceuticals by 83.9% in the 3rd quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock worth $27,000 after purchasing an additional 303 shares in the last quarter. Capital Performance Advisors LLP purchased a new position in shares of Ionis Pharmaceuticals in the third quarter worth $40,000. Prospera Private Wealth LLC acquired a new stake in shares of Ionis Pharmaceuticals during the third quarter worth $42,000. Itau Unibanco Holding S.A. grew its holdings in shares of Ionis Pharmaceuticals by 40.9% during the third quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company’s stock valued at $43,000 after buying an additional 314 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Ionis Pharmaceuticals in the 3rd quarter valued at $51,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.